White Paper

Optimizing Generative AI In Clinical Operations Through Focus, Restraint, And Maximized Validation

AI-artificial intelligence-GettyImages-1464561797

Last November, OpenAI released ChatGPT, their generative pre-trained transformer AI model, into the public domain, swiftly becoming the world’s most acclaimed chatbot. While the GenAI Large Language Model (LLM) wasn't new, ChatGPT's accessible interface and human-like outputs sparked global amazement, speculation, and concern. Media influencers often make grand predictions about GenAI, from solving global issues to heralding humanity's downfall.

Amidst the noise, this article aims to provide a clear-eyed view of GenAI's potential benefits and risks in medical research. It emphasizes the need for a focused framework to harness GenAI's potential in healthcare, prioritizing patient well-being. Applying restraint is crucial; as Miles Davis noted, success lies in what we choose not to pursue. In clinical trials, robust safeguards are essential to ensure patient safety and research integrity. IQVIA has meticulously studied GenAI's opportunities and challenges, developing a blueprint for its ethical integration into clinical trials. Therefore, careful consideration and fortified safeguards are paramount before implementing GenAI solutions.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

IQVIA Research & Development Solutions